Retatrutide, a new dual agonist of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) binding site , is showing promising results in preliminary human assessments . Ongoing research https://bookmarkpagerank.com/story21407113/retatrutide-emerging-research-and-possible-medical-roles